Shanghai Hile Bio-Technology Co., Ltd. (SHA:603718)
China · Delayed Price · Currency is CNY 3.840
0.00 (0.00%)
May 12, 2026, 3:00 PM CST
SHA:603718 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 173.47 | 187.87 | 271.02 | 231.35 | 294.12 | 346.15 |
Other Revenue | - | - | 0.02 | 9.37 | 5.87 | 1.14 |
| 173.47 | 187.87 | 271.04 | 240.72 | 299.99 | 347.29 | |
Revenue Growth (YoY) | -33.92% | -30.69% | 12.59% | -19.76% | -13.62% | 34.02% |
Cost of Revenue | 54.17 | 52.28 | 110.39 | 120.3 | 124.61 | 158.4 |
Gross Profit | 119.3 | 135.59 | 160.65 | 120.42 | 175.38 | 188.89 |
Selling, General & Admin | 60.77 | 65.48 | 111.95 | 99.77 | 126.85 | 129.9 |
Research & Development | 21.05 | 22.67 | 24.45 | 24.97 | 29.94 | 28.64 |
Other Operating Expenses | -0.68 | 0.37 | 2.17 | 1.4 | 3.33 | 3.5 |
Operating Expenses | 81.14 | 88.51 | 142.12 | 126.92 | 159.69 | 166.99 |
Operating Income | 38.16 | 47.07 | 18.53 | -6.5 | 15.69 | 21.9 |
Interest Expense | -0.12 | - | -5.49 | -5.39 | -10.31 | -12.38 |
Interest & Investment Income | - | 0.06 | 160.61 | 75.82 | 16.43 | 27.79 |
Currency Exchange Gain (Loss) | - | - | 10.3 | -0.01 | -0.06 | 0.28 |
Other Non Operating Income (Expenses) | 398.54 | 400.89 | -0.4 | -0.29 | 1.38 | -1.61 |
EBT Excluding Unusual Items | 436.59 | 448.02 | 183.55 | 63.63 | 23.14 | 35.99 |
Impairment of Goodwill | - | - | -1.19 | - | - | - |
Gain (Loss) on Sale of Investments | 4.08 | 4.53 | -12.76 | -16.52 | -2.97 | 8.28 |
Gain (Loss) on Sale of Assets | 0.38 | 0.34 | -0.71 | 0.55 | -0.36 | 7.41 |
Asset Writedown | -637.7 | -637.7 | - | - | - | - |
Other Unusual Items | - | - | 39.22 | 8.36 | 111.41 | 5.46 |
Pretax Income | -196.66 | -184.82 | 208.12 | 56.02 | 131.22 | 57.14 |
Income Tax Expense | 105.45 | 107.34 | 26.48 | 6.01 | 20.53 | 11.47 |
Earnings From Continuing Operations | -302.1 | -292.16 | 181.64 | 50.01 | 110.69 | 45.67 |
Minority Interest in Earnings | -13.9 | -19.28 | -10.46 | 12.86 | 10.92 | 8.19 |
Net Income | -316 | -311.44 | 171.18 | 62.87 | 121.61 | 53.86 |
Net Income to Common | -316 | -311.44 | 171.18 | 62.87 | 121.61 | 53.86 |
Net Income Growth | - | - | 172.28% | -48.30% | 125.80% | 503.33% |
Shares Outstanding (Basic) | 671 | 649 | 634 | 629 | 640 | 673 |
Shares Outstanding (Diluted) | 671 | 663 | 658 | 629 | 640 | 673 |
Shares Change (YoY) | -4.38% | 0.65% | 4.72% | -1.77% | -4.93% | -24.58% |
EPS (Basic) | -0.47 | -0.48 | 0.27 | 0.10 | 0.19 | 0.08 |
EPS (Diluted) | -0.47 | -0.48 | 0.26 | 0.10 | 0.19 | 0.08 |
EPS Growth | - | - | 160.00% | -47.37% | 137.50% | 700.00% |
Free Cash Flow | 59.16 | 46.66 | 38.08 | -16.18 | 273.06 | 5.85 |
Free Cash Flow Per Share | 0.09 | 0.07 | 0.06 | -0.03 | 0.43 | 0.01 |
Dividend Per Share | - | - | 0.078 | 0.029 | 0.057 | - |
Dividend Growth | - | - | 173.17% | -49.38% | - | - |
Gross Margin | 68.77% | 72.17% | 59.27% | 50.02% | 58.46% | 54.39% |
Operating Margin | 22.00% | 25.06% | 6.84% | -2.70% | 5.23% | 6.30% |
Profit Margin | -182.17% | -165.77% | 63.16% | 26.12% | 40.54% | 15.51% |
Free Cash Flow Margin | 34.10% | 24.84% | 14.05% | -6.72% | 91.02% | 1.69% |
EBITDA | 46.04 | 60.32 | 53.27 | 29.16 | 56.86 | 78.79 |
EBITDA Margin | 26.54% | 32.11% | 19.65% | 12.11% | 18.95% | 22.69% |
D&A For EBITDA | 7.87 | 13.25 | 34.74 | 35.66 | 41.17 | 56.9 |
EBIT | 38.16 | 47.07 | 18.53 | -6.5 | 15.69 | 21.9 |
EBIT Margin | 22.00% | 25.06% | 6.84% | -2.70% | 5.23% | 6.30% |
Effective Tax Rate | - | - | 12.72% | 10.73% | 15.64% | 20.08% |
Revenue as Reported | - | - | 271.04 | 240.72 | 299.99 | 347.29 |
Advertising Expenses | - | - | 3.81 | 3.22 | 3.67 | 3.73 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.